Cristina Pellegrini1, Maria Esposito1, Giovanni Schinzari2,3, Maria Concetta Fargnoli1, Ernesto Rossi4, Paolo Gisondi5, Stefano Piaserico6, Paolo Dapavo7, Andrea Conti8,9, Alessio Gambardella10, Martina Burlando11, Alessandra Narcisi12,13, Annamaria Offidani14, Riccardo Balestri15, Federico Bardazzi16, Francesca Prignano17, Cristina Mugheddu18, Marco Romanelli19, Giovanna Malara20. 1. Dermatology, Department of Applied Clinical and Biotechnological Sciences, University of L'Aquila, L'Aquila, Italy. 2. Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168, Rome, Italy. 3. Medical Oncology, Università Cattolica del S. Cuore, Rome, Italy. 4. Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168, Rome, Italy. ernestorossi.rm@gmail.com. 5. Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy. 6. Dermatology Unit, Department of Medicine, University of Padova, Padua, Italy. 7. S.C. Dermatologia U, AOU Città della Salute e della Scienza di Torino, Torino, Italy. 8. Dermatologic Unit, Department of General Surgery, Infermi Hospital, Rimini, RN, Italy. 9. AUSL Romagna, Romagna, Italy. 10. Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Caserta, Italy. 11. Department of Dermatology, Dipartimento di scienze della salute - DISSAL Ospedale Policlinico San Martino, University of Genoa, Genova, Italy. 12. Dermatology, Humanitas Clinical and Research Center-IRCCS, Rozzano, Milan, Italy. 13. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. 14. Department of Clinical and Molecular Sciences, Dermatology Unit, Polytechnic Marche, University, Ancona, Italy. 15. Division of Dermatology, Hospital of Trento, Trento, Italy. 16. Dermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine Alma Mater Studiorum, IRCCS Azienda Ospedaliero Universitaria Bologna, University of Bologna, Bologna, Italy. 17. Department of Health Science, Dermatology Unit, University of Florence, Florence, Italy. 18. Section of Dermatology, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy. 19. Department of Dermatology, University of Pisa, Pisa, Italy. 20. Dermatology Department, Grande Ospedale Metropolitano "BMM" Reggio Calabria, Reggio Calabria, Italy.
Abstract
INTRODUCTION: There is limited evidence to guide clinicians on the treatment of psoriasis with biologics in patients with a history of malignancy who are often excluded from clinical trials investigating biologics. The aim of this work is to report a multicenter real-life experience of secukinumab treatment in patients with psoriasis and a personal history of cancer. METHODS: This retrospective observational study included adult patients with moderate-to-severe plaque psoriasis treated with secukinumab for at least 24 weeks and a previous diagnosis of cancer at 15 Italian referral centers. The primary endpoint of the study was tumor recurrence or progression and new cancer diagnosis during treatment. Secondary outcome assessment of secukinumab effectiveness (reduction of Psoriasis Area and Severity Index [PASI] score, improvement of Dermatology Life Quality Index [DLQI], itch and pain). RESULTS: Forty-two patients (27 male) were included. Malignancy was diagnosed in the previous 5 years in 21 (56.8%) and in the previous 10 years in 37 (88.1%). The mean interval between cancer diagnosis and the start of secukinumab treatment was 3.5 ± 3.3 years. No tumor recurrence nor progression occurred over a mean of 56 ± 31.7 weeks of treatment. Three patients developed a new malignancy not related to the previous cancer. At week 48, PASI 90 was reached by 64.7% of patients and PASI 100 by 38.2%. Mean DLQI, itch, and pain VAS scores significantly improved during treatment. CONCLUSIONS: Our multicenter real-life experience is the largest reported to date focusing on a specific biologic and adds evidence to the safety of secukinumab in psoriatic patients with a personal history of cancer.
INTRODUCTION: There is limited evidence to guide clinicians on the treatment of psoriasis with biologics in patients with a history of malignancy who are often excluded from clinical trials investigating biologics. The aim of this work is to report a multicenter real-life experience of secukinumab treatment in patients with psoriasis and a personal history of cancer. METHODS: This retrospective observational study included adult patients with moderate-to-severe plaque psoriasis treated with secukinumab for at least 24 weeks and a previous diagnosis of cancer at 15 Italian referral centers. The primary endpoint of the study was tumor recurrence or progression and new cancer diagnosis during treatment. Secondary outcome assessment of secukinumab effectiveness (reduction of Psoriasis Area and Severity Index [PASI] score, improvement of Dermatology Life Quality Index [DLQI], itch and pain). RESULTS: Forty-two patients (27 male) were included. Malignancy was diagnosed in the previous 5 years in 21 (56.8%) and in the previous 10 years in 37 (88.1%). The mean interval between cancer diagnosis and the start of secukinumab treatment was 3.5 ± 3.3 years. No tumor recurrence nor progression occurred over a mean of 56 ± 31.7 weeks of treatment. Three patients developed a new malignancy not related to the previous cancer. At week 48, PASI 90 was reached by 64.7% of patients and PASI 100 by 38.2%. Mean DLQI, itch, and pain VAS scores significantly improved during treatment. CONCLUSIONS: Our multicenter real-life experience is the largest reported to date focusing on a specific biologic and adds evidence to the safety of secukinumab in psoriatic patients with a personal history of cancer.
Authors: Diamant Thaçi; Andrew Blauvelt; Kristian Reich; Tsen-Fang Tsai; Francisco Vanaclocha; Külli Kingo; Michael Ziv; Andreas Pinter; Sophie Hugot; Ruquan You; Marina Milutinovic Journal: J Am Acad Dermatol Date: 2015-06-17 Impact factor: 11.527
Authors: Peter C M van de Kerkhof; Christopher E M Griffiths; Kristian Reich; Craig L Leonardi; Andrew Blauvelt; Tsen-Fang Tsai; Yankun Gong; Jiaqing Huang; Charis Papavassilis; Todd Fox Journal: J Am Acad Dermatol Date: 2016-05-12 Impact factor: 11.527
Authors: M Valenti; G Pavia; L Gargiulo; P Facheris; F Sanna; R G Borroni; A Costanzo; A Narcisi Journal: J Dermatolog Treat Date: 2021-02-15 Impact factor: 3.230